SCHEMBL2922344

SCHEMBL2922344

CC(C)(C)c1cc(NC(=O)Nc2cc(Oc3nccc(-c4cn[nH]c4)n3)ccc2F)n(-c2ccc(F)c(C#N)c2)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 15/20 0.47
MAPK14 Q16539 5/20 0.46
NTRK1 P04629 2/20 0.45
NTRK3 Q16288 2/20 0.45
NTRK2 Q16620 2/20 0.45
PLK4 O00444 1/20 0.45
ACOX3 O15254 1/20 0.45
MAP3K7 O43318 1/20 0.45
DYRK3 O43781 1/20 0.45
JAK2 O60674 1/20 0.45
ERN1 O75460 1/20 0.45
RPS6KA4 O75676 1/20 0.45
STK10 O94804 1/20 0.45
MAP4K4 O95819 1/20 0.45
ABL1 P00519 1/20 0.45
RAF1 P04049 1/20 0.45
LCK P06239 1/20 0.45
FYN P06241 1/20 0.45
CDK1 P06493 1/20 0.45
FES P07332 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5066526 0.95 MAPK14 (0.47) BRAFMAPK14NTRK1NTRK3NTRK2
SCHEMBL2926831 0.91 MAPK14 (0.49) BRAFMAPK14NTRK1NTRK3NTRK2
SCHEMBL5063053 0.90 MAPK14 (0.45) BRAFMAPK14NTRK1NTRK3NTRK2
SCHEMBL5063126 0.86 BRAF (0.46) BRAFMAPK14KCNH2
SCHEMBL3663374 0.86 MAPK14 (0.54) BRAFMAPK14NTRK1ABL1RAF1
SCHEMBL5066537 0.85 MAPK14 (0.46) BRAFMAPK14NTRK1NTRK3NTRK2
SCHEMBL3041186 0.82 MAPK14 (0.57) BRAFMAPK14NTRK1NTRK3NTRK2
SCHEMBL2926463 0.81 BRAF (0.40) BRAFMAPK14MAP3K7SRCSYK
SCHEMBL2924836 0.81 MAPK14 (0.48) BRAFMAPK14NTRK1NTRK3NTRK2
SCHEMBL11889078 0.80 BRAF (0.38) BRAFMAPK14NTRK1NTRK3NTRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2481736-A1 Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases Deciphera Pharmaceuticals, LLC. (US) 2012-08-01 EP disclosed
EP-2148677-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES Deciphera Pharmaceuticals, LLC. (US) 2010-02-03 EP disclosed
US-20080269267-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2008-10-30 US disclosed
WO-2008131276-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2008-10-30 WO disclosed
EP-1928861-A1 4- (IH-INDAZOL-S-YL-AMINO)-QUINAZOLINE COMPOUNDS AS ERBB RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER AstraZeneca AB (SE) 2008-06-11 EP disclosed
WO-2007034144-A1 4- (IH-INDAZOL-S-YL-AMINO)-QUINAZOLINE COMPOUNDS AS ERBB RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2007-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269267-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES BRAF, RET, KIT BRAF 1/4885MAPK14 281/4885NTRK1 151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.